Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -47.02M | -60.53M | -27.13M | -18.48M | -27.15M |
Total Depreciation and Amortization | 683.00K | 810.00K | 890.00K | 956.00K | 997.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 3.35M | 22.54M | 3.01M | 4.04M | 5.41M |
Change in Net Operating Assets | 215.00K | 8.93M | 2.11M | -6.36M | -2.50M |
Cash from Operations | -42.77M | -28.25M | -21.12M | -19.84M | -23.25M |
Capital Expenditure | -220.00K | -61.00K | -221.00K | -16.00K | -90.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 31.50M | -4.13M | -13.13M | -2.31M | -21.94M |
Cash from Investing | 31.28M | -4.19M | -13.35M | -2.33M | -22.03M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -- | 239.00K | 0.00 | -- | 119.88M |
Repurchase of Common Stock | -- | -- | -- | -116.00K | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -- | 239.00K | 0.00 | -116.00K | 119.88M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -11.49M | -32.20M | -34.47M | -22.29M | 74.61M |